Ayala Pharmaceuticals, Inc.

Equities

ADXS

US0076244062

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:25:38 25/06/2024 BST			5-day change	1st Jan Change
0.21 ^USD	+22.81%		-16.03%	-68.52%

04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Advaxis, Inc. Reports Earnings Results for the Full Year Ended October 31, 2020

January 22, 2021 at 09:39 pm

Advaxis, Inc. announced earnings results for the full year ended October 31, 2020. For the full year, the company announced sales was USD 253,000 compared to USD 20.884 million a year ago. Operating loss was USD 26.449 million compared to USD 17.972 million a year ago. Net loss was USD 26.469 million compared to USD 16.612 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 1.09 a year ago.

Latest news about Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	04-03	CI
Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	04-03	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	03-24	CI
North American Morning Briefing : Fed's Preferred -2-	02-29	DJ
North American Morning Briefing : Nvidia Ignites -2-	02-22	DJ
Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	02-20	CI
Sector Update: Health Care Stocks Gain Late Afternoon	02-06	MT
Top Midday Gainers	02-06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	02-06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	02-05	CI
North American Morning Briefing : Stock Futures -2-	11-27	DJ
Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	11-20	DJ
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023	23/10/23	CI
Ayala Pharmaceuticals, Inc. Announces Executive Changes	20/10/23	CI
BioSight Ltd. acquired Ayala Pharmaceuticals, Inc. in a reverse merger transaction.	17/10/23	CI
North American Morning Briefing : Stock Futures Point Lower Ahead of Big Bank Earnings	13/10/23	DJ
North American Morning Briefing : Investors Await -2-	06/10/23	DJ
North American Morning Briefing : Mood Improves as -2-	29/09/23	DJ
North American Morning Briefing : Stock Futures -2-	22/09/23	DJ

Chart Ayala Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.21

Average target price

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AYALA PHARMACEUTICALS, INC.	-68.52%	8.95M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+38.59%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research